Combos Mark Next Step in Melanoma Immunotherapy

Source: OncLive, February 2017

Evidence continues to build for the long-term efficacy of PD-1–targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response, according to Tara C. Gangadhar, MD. The future will bring an increased focus on novel combinations and more informative biomarkers.

Those insights were among the observations that Gangadhar made during a presentation at the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® that Physicians’ Education Resource® (PER®) hosted in Sunny Isles Beach, Florida, on February 11.

Single-agent PD-1 blockade with nivolumab (Opdivo) or pembrolizumab (Keytruda) has become a standard- of-care first-line option for patients with metastatic or unresectable melanoma in the National Comprehensive Cancer Network guidelines, noted Gangadhar.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories